N-(5-acetyl-pyrazin-2-yl)-2,2-dimethyl-propionamide | 710322-29-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(5-acetyl-pyrazin-2-yl)-2,2-dimethyl-propionamide
• 英文别名: N-(5-acetylpyrazin-2-yl)-2,2-dimethylpropanamide
• CAS: 710322-29-5
• 化学式: C₁₁H₁₅N₃O₂
• 分子量: 221.259
• InChiKey: PTQJLVOATZBNQK-UHFFFAOYSA-N

物化性质

• 沸点：
  418.3±45.0 °C(Predicted)
• 密度：
  1.164±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  72
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(5-acetyl-pyrazin-2-yl)-2,2-dimethyl-propionamide 在 甲醇 、 potassium carbonate 作用下， 生成 1-(5-氨基-2-吡嗪基)乙酮
  参考文献：
  名称：

  EP2236498

  摘要：

  公开号：
• 作为产物：
  描述：

  三甲基乙酰氯 在 吡啶 、 bis-triphenylphosphine-palladium(II) chloride 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 15.0h， 生成 N-(5-acetyl-pyrazin-2-yl)-2,2-dimethyl-propionamide
  参考文献：
  名称：

  Identification of RO4597014, a Glucokinase Activator Studied in the Clinic for the Treatment of Type 2 Diabetes

  摘要：

  To resolve the metabolite redox cycling associated with our earlier clinical compound 2, we carried out lead optimization of lead molecule 1. Compound 4 showed improved lipophilic ligand efficiency and demonstrated robust glucose lowering in diet-induced obese mice without a liability in predictive preclinical drug safety studies. Thus, it was selected as a clinical candidate and further studied in type 2 diabetic patients. Clinical data suggests no evidence of metabolite cycling, which is consistent with the preclinical profiling of metabolism.

  DOI：

  10.1021/ml400027y

文献信息

• [EN] 5-SUBSTITUTED-PYRAZINE OR PYRIDINE GLUCOKINASE ACTIVATORS<br/>[FR] ACTIVATEURS DE LA GLUCOKINASE A BASE DE PYRAZINE OU DE PYRIDINE SUBSTITUEES EN POSITION 5
  申请人：HOFFMANN LA ROCHE

  公开号：WO2004052869A1

  公开（公告）日：2004-06-24

  The present invention provides a compound according to formula (I) where the substituent designations are provided in the specification. Pharmaceutical compositions comprising a compound according to formula (I) are also provided, said compounds being glucokinase activators which are useful in the treatment of type II diabetes.

  本发明提供了一种化合物，其化学式为（I），其中取代基的定义在说明书中提供。还提供了包括符合化学式（I）的化合物的药物组合物，这些化合物是葡萄糖激酶激活剂，对于治疗2型糖尿病是有用的。
• 5-Substituted-six-membered heteroaromatic glucokinase activators
  申请人：——

  公开号：US20040147748A1

  公开（公告）日：2004-07-29

  The present invention provides a compound according to formula I 1 where the substituent designations are provided in the specification. Pharmaceutical compositions comprising a compound according to formula I are also provided.

  本发明提供了一种化合物，其化学式为I1，其中取代基的具体说明在规范中提供。还提供了包含化合物I的制药组合物。
• 5-substituted-six-membered heteroaromatic glucokinase activators
  申请人：Hoffmann-La Roche Inc.

  公开号：US07132425B2

  公开（公告）日：2006-11-07

  The present invention provides a compound according to formula I where the substituent designations are provided in the specification. Pharmaceutical compositions comprising a compound according to formula I are also provided.

  本发明提供了一个化合物，其化学式为I，其中置换基的定义在说明书中提供。还提供了包含化学式I的化合物的药物组合物。
• Substituted pyrazine compounds
  申请人：Astellas Pharma Inc.

  公开号：US08329707B2

  公开（公告）日：2012-12-11

  Phenylacetamide compounds of the formula having sulfonyl group and cycloalkyl group on the phenyl group and having heteroaryl group on the nitrogen atom in the amide have an excellent glucokinase activation action.

  具有苯基上磺酰基和环烷基，并在酰胺中的氮原子上具有杂环基的苯乙酰胺化合物具有出色的葡萄糖激酶激活作用。
• METHOD OF TREATING DIABETES, METABOLIC SYNDROME AND OBESITY USING PHENYLACETAMIDE DERIVATIVE
  申请人：Hayakawa Masahiko

  公开号：US20130102617A1

  公开（公告）日：2013-04-25

  Phenylacetamide compounds of the formula having sulfonyl group and cycloalkyl group on the phenyl group and having heteroaryl group on the nitrogen atom in the amide have an excellent glucokinase activation action. The compound of the present invention is useful as an agent for treating diabetes, in particular, type II diabetes, as well as metabolic syndrome and obesity.

  具有苯基上磺酰基和环烷基，以及在酰胺中氮原子上具有杂环基团的苯乙酰胺化合物，具有优异的葡萄糖激酶激活作用。本发明的化合物可用作治疗糖尿病，特别是2型糖尿病以及代谢综合征和肥胖症的药物。